NMPA accepts zanidatamab BLA in China; Zymeworks earns $8M milestone from BeiGene

Zymeworks Inc.

China's NMPA accepted BLA for zanidatamab in second-line HER2+ biliary tract cancer.
Acceptance triggers $8 million milestone payment from partner BeiGene under Asia Pacific license.
FDA previously granted priority review for same indication; PDUFA target date Nov 29, 2024.
Zanidatamab is also being developed by Jazz Pharmaceuticals in the U.S.
Milestone payment expected to be received following NMPA acceptance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.